Clinical Trial Update: Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating nilotinib in patients with metastatic mucosal, acral, or chronically sun-damaged melanoma who are resistant or intolerant to TKIs; stud…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acral Melanoma
• Melanoma
• Mucosal Melanoma

Drugs mentioned

• Nilotinib (nilotinib)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Mucosal Lentiginous Melanoma, Acral Melanoma | Phase 2 | Status: COMPLETED | Results posted: 2016-12-08